Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids -

• Status: Recruiting
• Trial end date: 2021-04-30
• Target enrollment: 0
• Participant gender: All

Summary

A study on patients who are hospitalized and tested positive for COVID-19 or have a typical CT image of COVID-19 infection, to establish if omega-3 Polyunsaturated Fatty Acid (PUFA) supplementation by intravenous route is a possible treatment option in COVID-19 with minimal risks to the patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Karolinska University Hospital

Criteria

Inclusion Criteria:

1. Provision of signed informed consent prior to any study specific procedures.

2. Female and male patients ≥18 years of age.

3. COVID-19 positive or typical CT image of COVID-19 infection.

4. Clinical status requiring hospitalization.

Exclusion Criteria:

1. According to Omegaven® contraindications (serious bleeding disorders, acute life-threatening condition, including acute shock, acute myocardial infarction, acute stroke, acute emboli, and coma).

2. Known hypersensitivity to Omegaven® or any of the ingredients.

3. Participation in any clinical research study evaluating an investigational medicinal product (IMP) within 3 months prior to screening.

4. Pregnancy and breastfeeding.